Loading...
•
Jun 30, 2023
Esperion Q2 2023 Earnings Report
Esperion's Q2 2023 financial results reflected strong prescription growth and strategic plan execution.
Key Takeaways
Esperion reported a 37% increase in total revenue for Q2 2023, driven by a 49% increase in U.S. net product revenue. The company submitted applications for expanded indications in the U.S. and Europe and presented new data demonstrating significant cardiovascular risk reduction.
U.S. net product revenue grew 49% year-over-year to $20.3 million.
Retail prescription equivalents grew 26% year-over-year.
New to brand prescriptions grew 28% quarter-over-quarter.
Applications for expanded indications in the U.S. and Europe were submitted, with label changes expected in the first half of 2024.
Revenue by Segment
Forward Guidance
The company expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...